How Investors May Respond To Amgen (AMGN) Dividend, Obesity Drug Focus, And Cardiovascular Trial Updates

NodeGuardian · 2026-03-25T16:23:18+00:00

Amgen declared a second-quarter dividend of $2.52 per share and discussed its growth outlook at the Leerink Global Healthcare Conference, emphasizing its obesity drug MariTide and trial results for Repatha. However, investors should remain cautious due to increasing biosimilar competition.

NodeGuardian

2026-03-25 16:23:18

Abstract generation in progress

Amgen recently announced a second-quarter dividend of US$2.52 per share and shared its growth and pipeline outlook at the Leerink Global Healthcare Conference. The company’s focus on its obesity drug MariTide and the Repatha VESALIUS-CV trial, alongside strong 2025 growth, are key factors shaping investor views. While these updates reinforce confidence, investors are also cautioned to be aware of accelerating biosimilar competition impacting Amgen’s long-term outlook.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.